Daratumumab (anti-CD38)

製品コード：A2027         Batch: A202703

印刷

Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.

製品説明

CAS No. 945721-28-8
Formulation PBS Buffer, PH 7.4
Isotype Human IgG1
Source Human
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 10.07 mg/ml
Endotoxin Level ＜1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology [ Leuk Res, 2024, 147:107599] PubMed: 39486120
Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro [ Brain Behav Immun Health, 2024, 42:100865] PubMed: 39411424
Neutralization of BAFF and APRIL with engineered soluble BCMA decoy receptor for the treatment of B-cell malignancies [ Oxford University Research Archive, 2023, ] PubMed: None
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma [ J Exp Med, 2022, 219(9)e20220214] PubMed: 35881112
Aberrant BCMA signaling promotes tumor growth by altering protein translation machinery, a therapeutic target for the treatment of relapse/refractory multiple myeloma [ bioRxiv, 2022, 10.1101/2021.05.03.442500] PubMed: None

人間や獣医の診断であるか治療的な使用のためにでない。